APA (7th ed.) Citation

Kister, I., Curtin, R., Piquet, A. L., Borko, T., Pei, J., Banbury, B. L., . . . Silverman, G. J. (2024). Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination. Annals of Clinical & Translational Neurology, 11(7), 1750. https://doi.org/10.1002/acn3.52081

Chicago Style (17th ed.) Citation

Kister, Ilya, et al. "Longitudinal Study of Immunity to SARS‐CoV2 in Ocrelizumab‐treated MS Patients Up to 2 years After COVID‐19 Vaccination." Annals of Clinical & Translational Neurology 11, no. 7 (2024): 1750. https://doi.org/10.1002/acn3.52081.

MLA (9th ed.) Citation

Kister, Ilya, et al. "Longitudinal Study of Immunity to SARS‐CoV2 in Ocrelizumab‐treated MS Patients Up to 2 years After COVID‐19 Vaccination." Annals of Clinical & Translational Neurology, vol. 11, no. 7, 2024, p. 1750, https://doi.org/10.1002/acn3.52081.